WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, being held June 19-20, 2019, at the St. Regis New York Hotel in New York City.
Bellerophon Presentation Details
|
| Date: |
|
|
|
Thursday, June 20 |
| Time: |
|
|
|
11:00 AM Eastern Time |
| Location: |
|
|
|
St. Regis New York Hotel, New York, NY |
| Webcast: |
|
|
|
http://wsw.com/webcast/jmp39/blph/ |
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
| Contacts |
|
|
|
|
| At Bellerophon: |
|
|
|
At LifeSci Advisors: |
| Fabian Tenenbaum, Chief Executive Officer |
|
|
|
Brian Ritchie |
| (908) 574-4767 |
|
|
|
(212) 915-2578 |
| |
|
|
|
britchie@lifesciadvisors.com |
Source: Bellerophon Therapeutics, Inc.